Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report

doi:10.5306/wjco.v15.i7.945

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

(134)

(144)

(0)

(13)

(2488)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Jul 24, 2024; 15(7): 945-952
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.945

Full Size Figure Download Figure

Figure 3 Serial computed tomography images. A: Computed tomography (CT) after postoperative recurrence; B: CT after 1 month of gefitinib therapy. Progressive disease of the lung was detected; C: CT after 53 months of crizotinib therapy. Stable disease was detected.

Citation: Peng GQ, Song HC, Chen WY. Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report. World J Clin Oncol 2024; 15(7): 945-952
URL: https://www.wjgnet.com/2218-4333/full/v15/i7/945.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i7.945

Peng GQ, Song HC, Chen WY. Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report. World J Clin Oncol 2024; 15(7): 945-952 [PMID: 39071469 DOI: 10.5306/wjco.v15.i7.945]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.